集團產品精選影片
-
實現Taiwan can help！聯亞生技UB-612新冠疫苗三期臨床試驗達標，將向英國MHRA及澳洲TGA申請許可！
實現Taiwan can help！聯亞生技UB-612新冠疫苗三期臨床試驗達標，將向英國MHRA及澳洲TGA申請許可！實現Taiwan can help！聯亞生技UB-612新冠疫苗三期臨床試驗達標，將向英國MHRA及澳洲TGA申請許可！more -
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptoms
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptomsIgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptomsmore -
Essential version- UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity
Essential version- UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell ImmunityEssential version- UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunitymore -
全球首創精準設計之廣譜新冠疫苗UB-612，優異臨床數據獲國際權威期刊《臨床研究期刊》肯定
全球首創精準設計之廣譜新冠疫苗UB-612，優異臨床數據獲國際權威期刊《臨床研究期刊》肯定全球首創精準設計之廣譜新冠疫苗UB-612，優異臨床數據獲國際權威期刊《臨床研究期刊》肯定more
